Quinupristin

From WikiMD's WELLNESSPEDIA

Quinupristin.png

Quinupristin is a streptogramin antibiotic used in combination with dalfopristin to form the drug quinupristin/dalfopristin, marketed under the brand name Synercid. This combination is used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE).

Mechanism of Action[edit]

Quinupristin belongs to the streptogramin class of antibiotics, which are divided into two groups: streptogramin A and streptogramin B. Quinupristin is a streptogramin B antibiotic. It works by binding to the 50S ribosomal subunit of the bacterial ribosome, inhibiting protein synthesis. When used in combination with dalfopristin, a streptogramin A antibiotic, the two drugs exhibit a synergistic effect, enhancing their antibacterial activity.

Clinical Uses[edit]

Quinupristin/dalfopristin is primarily used to treat severe infections caused by Gram-positive bacteria, particularly those resistant to other antibiotics. It is effective against:

Administration and Dosage[edit]

Quinupristin/dalfopristin is administered intravenously. The typical dosage is 7.5 mg/kg every 8 to 12 hours, depending on the severity of the infection and the patient's renal function.

Side Effects[edit]

Common side effects of quinupristin/dalfopristin include:

Serious side effects may include hepatotoxicity and thrombophlebitis.

Resistance[edit]

Bacterial resistance to quinupristin can occur through various mechanisms, including:

  • Modification of the target site on the 50S ribosomal subunit
  • Enzymatic inactivation of the antibiotic
  • Efflux pumps that expel the antibiotic from the bacterial cell

History[edit]

Quinupristin was developed as part of the effort to find new antibiotics effective against resistant strains of bacteria. It was approved for medical use in combination with dalfopristin in the late 1990s.

See Also[edit]

References[edit]


External Links[edit]

Quinupristin































Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.